Colorectal LLM Wiki

Browse
Home / Sources / ASCRS Ch31 - Colorectal Cancer Management of Distant Metastases
Source created 2026-08-25 · updated 2026-08-25
colorectalcolon-cancerrectal-cancermetastatic-diseaseliver-metastaseslung-metastasestextbook

ASCRS Ch31 - Colorectal Cancer Management of Distant Metastases

Chapter 31 of the ASCRS Textbook of Colon and Rectal Surgery, 4th edition (Hedrick TL). Book pp. 547–559. Thirty-first chapter overall — the textbook's dedicated treatment of stage IV (metastatic) colorectal cancer, following Chapter 30's postoperative adjuvant/surveillance content for stage I–III disease.

Textbook reference chapter — not primary literature; individual cited trials/series (OSLO-COMET, LIGRO, FOXFIRE/SIRFLOX/FOXFIRE-Global, Martin et al.'s FOLFOX-DEBIRI RCT, the SEER database analysis, the PulMiCC and JCOG1007/CAIRO4/GRECCAR 8 trials, the STS Expert Consensus Task Force) are named and their headline results reported, but none are independently ingested from primary publications.

Key content

  • Epidemiology: up to 22% of CRC patients present with metastatic disease; liver is the dominant metastatic site (75%), followed by lung (22%); over 70% of patients with lung metastases also have synchronous liver metastases. 5-year survival in stage IV CRC ranges 10–14% overall, but 24–58% (averaging 40%) with resectable hepatic metastases.
  • Synchronous metastases: Fig. 31.1 treatment algorithm (multidisciplinary discussion → resectable/unresectable + symptomatic/asymptomatic primary branching → stent/divert/resect vs. chemotherapy → reimaging every 8 weeks for conversion). Management of the primary tumor (bleeding, obstruction — stenting vs. resection vs. diversion decision factors, stent patency ~106 days median, a philosophical shift away from prophylactic primary resection in asymptomatic unresectable disease [84% in 2000 → 52% in 2011]; perforation). Unresectable synchronous metastases (chemotherapy-first philosophy, FOLFOX/FOLFIRI/CAPEOX/FOLFOXIRI ± bevacizumab regimens, resection-first vs. chemo-first tradeoffs, ongoing trials JCOG1007/CAIRO4/GRECCAR 8). Resectable synchronous metastases (Fig. 31.3 NCCN-guideline-based clinical vignettes for sequencing colectomy/hepatectomy/chemotherapy). Rectal cancer-specific sequencing considerations (adding pelvic radiotherapy to the sequencing question).
  • Metachronous metastases: ~20% of patients develop metachronous metastases after initial curative treatment (vs. ~20% presenting with synchronous disease at diagnosis); >85% diagnosed within 3 years; liver most common site (60%) followed by lungs (39%), extra-regional lymph nodes (22%), peritoneum (19%). Predictors: male gender, advanced primary T-stage, N-stage, high-grade differentiation, and positive/unknown resection margin (each with hazard ratios given). Better prognosis than synchronous disease overall.
  • Liver metastases — Resection: FLR (future liver remnant) volume and PVE (portal vein embolization)-achieved hypertrophy as predictors of surgical outcome; ALPPS (liver partition + portal venous ligation for staged hepatectomy) as an emerging technique with higher resection rates but more complications than conventional staged hepatectomy (LIGRO trial); OSLO-COMET trial data showing laparoscopic liver resection's shorter hospital stay, lower complications, better QoL, and equivalent long-term oncologic outcomes vs. open resection.
  • Liver metastases — Locoregional therapies: Table 31.1 (a full modality-comparison table: resection, RFA, MWA, TACE ± drug-eluting beads, TARE/SIRT, SBRT, chemotherapy alone — mechanism, indication, survival, risks for each). Martin et al.'s FOLFOX-DEBIRI RCT (higher response/downsizing rates, no PFS/OS difference). FOXFIRE/SIRFLOX/FOXFIRE-Global pooled analysis (higher toxicity, no OS benefit from adding SIRT/⁹⁰Y to FOLFOX). SBRT phase II and registry data.
  • Lung metastases: no single prospective trial has evaluated pulmonary metastasectomy efficacy (practice patterns from retrospective series/registries only); the ongoing PulMiCC trial randomizes resection vs. surveillance. STS Expert Consensus Task Force (modified Delphi) and NCCN recommendations. Mediastinal LN metastases in up to 44% of pulmonary-metastasis patients; PM morbidity 11%, mortality 1.1%.
  • Other sites of metastases: Ovarian (5–10% of women with CRC; Krukenberg tumor terminology; immunohistochemistry differentiating primary ovarian vs. metastatic CRC; NCCN's move away from prophylactic oophorectomy). Brain (1–4%; surgery/WBRT/SRS, SRS now preferred adjuvant modality). Adrenal (rare, usually late-course; surgery rarely an option, occasional case-report survival with resection of isolated adrenal metastases).
  • Surveillance after metastatic-CRC curative-intent treatment: paucity of dedicated data; NCCN suggests the same strategy as stage II/III with more frequent cross-sectional imaging (H&P q3–6mo for 2yrs then q6mo to 5yrs; CEA q3–6mo for 2yrs then q6mo to 5yrs; chest/abdomen/pelvis CT q3–6mo for 2yrs then q6–12mo to 5yrs; colonoscopy 1yr after surgery).

Wiki integration

Backs a new concept page, Management of Colorectal Cancer Distant Metastases — the wiki's first dedicated treatment of metastatic-CRC surgical/procedural management. Cross-linked into (not duplicating) Rectal Cancer's existing Metastatic disease systemic-chemotherapy-regimen paragraph, which remains the authoritative home for that regimen framework.